Physician profile
Alvaro E Pena
NPI 1447220959
$13,796.20
in general payments reported to CMS, 2019-2025
32 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $1,436 · 2021: $2,245 · 2022: $1,978 · 2023: $1,968 · 2024: $2,279 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,279.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,517.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,140.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,002.25 | 2021-2025 | |
| Lilly USA, LLC | $1,429.17 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $813.68 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.68 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $566.10 | 2019-2023 | |
| Amgen INC. | $433.02 | 2019-2025 | Evenity, Prolia, Repatha |
| Phathom Pharmaceuticals, INC. | $422.95 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $367.54 | 2019-2025 | Zoryve, Livalo |
| Corcept Therapeutics | $330.86 | 2022-2025 | Korlym |
| Astellas Pharma US INC | $313.74 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $308.73 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $274.29 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $176.95 | 2019-2024 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $154.89 | 2022 | |
| Abbott Laboratories | $148.55 | 2024-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $133.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $117.55 | 2019-2020 | |
| Exact Sciences Corporation | $108.29 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.09 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $88.04 | 2019-2022 | |
| Allergan, INC. | $75.19 | 2019-2020 | |
| Hologic Sales and Service, LLC | $40.19 | 2019-2023 | Aptima, Thinprep 2000 Processor |
| Watermark Medical, INC. | $29.10 | 2022 | |
| Echosens North America, INC. | $26.63 | 2025 | Fibroscan |
| Teva Pharmaceuticals USA, INC. | $23.11 | 2019 | |
| Medicure Pharma INC. | $17.47 | 2021 | |
| Cranial Technologies, INC | $16.22 | 2024 | Doc Band |
| Amarin Pharma, INC. | $15.27 | 2021 | |
| Sanofi Pasteur INC. | $13.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvaro Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.